Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Common Equity (2016 - 2025)

Organogenesis Holdings has reported Common Equity over the past 10 years, most recently at $300.1 million for Q4 2025.

  • Quarterly results put Common Equity at $300.1 million for Q4 2025, up 14.16% from a year ago — trailing twelve months through Dec 2025 was $300.1 million (up 14.16% YoY), and the annual figure for FY2025 was $300.1 million, up 14.16%.
  • Common Equity for Q4 2025 was $300.1 million at Organogenesis Holdings, up from $255.1 million in the prior quarter.
  • Over the last five years, Common Equity for ORGO hit a ceiling of $300.1 million in Q4 2025 and a floor of $153.0 million in Q1 2021.
  • Median Common Equity over the past 5 years was $259.6 million (2022), compared with a mean of $249.0 million.
  • Biggest five-year swings in Common Equity: surged 448.65% in 2021 and later dropped 12.63% in 2025.
  • Organogenesis Holdings' Common Equity stood at $241.3 million in 2021, then grew by 10.08% to $265.7 million in 2022, then rose by 4.89% to $278.7 million in 2023, then decreased by 5.66% to $262.9 million in 2024, then grew by 14.16% to $300.1 million in 2025.
  • The last three reported values for Common Equity were $300.1 million (Q4 2025), $255.1 million (Q3 2025), and $233.2 million (Q2 2025) per Business Quant data.